Xiaoling Zhou

Xiaoling Zhou


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
WCWenjun Cai
Wenjun Cai
LJLili Jiang
Lili Jiang
CZChangwei Zhao
Changwei Zhao
XZXiaoling Zhou
Xiaoling Zhou
Metabolic bone disease (MBD), as one of the most severe metabolic disorders, remains a focal point and challenge in medical research. Numerous studies have demonstrated the efficacy of Traditional Chinese Medicine (TCM) in preventing and treating MBD. However, the inherent complexity of TCM metabolites poses significant limitations in elucidating their mechanisms of action. The advancement of omics technologies, including metabolomics, proteomics, and transcriptomics, has greatly facilitated research on MBD. These approaches enable the identification of potential biomarkers and the exploration of metabolic pathways and mechanisms underlying TCM interventions for MBD. Evidence indicates that TCM monomers, single botanical drugs, and herbal formulations are effective, safe, and well-tolerated in MBD prevention and treatment. This review summarizes recent applications and key findings of transcriptomics, proteomics, and metabolomics in studying the mechanisms of TCM interventions for MBD. It highlights the role of omics technologies in uncovering relevant metabolites and pathways under TCM treatment, providing valuable insights and clinical references for TCM-based strategies in managing MBD.

7 April 2025 in Biological Trace Element Research
Verified
Journal Article
Open access
PDF file
TGTianQi Gao
TianQi Gao
TCTianYang Chen
TianYang Chen
CAChengLong Ai
ChengLong Ai
YGYan Gu
Yan Gu
YWYunPeng Wang
YunPeng Wang
CZChangwei Zhao
Changwei Zhao
There is a clear relationship between osteoarthritis (OA) and micronutrients. Excessive accumulation of micronutrients may play a negative role in aggravating the symptoms of OA. This study aims to sort out the causal relationship between micronutrients (zinc, copper, magnesium, vitamins A, C, E, D, B6, and B12, folic acid, iron, carotene, selenium, calcium, and potassium) and OA. This study used Mendelian randomization (MR) to combining the causal relationship between micronutrients and the risk of OA. Micronutrient-related variants were extracted from a large-scale genome-wide association study (GWAS) database of circulating micronutrients in European populations. Outcome data were from the FINNGEN meta-analysis of OA in participants of European ancestry from the FinnGen Biobank in Finland. The primary analysis was performed using the inverse-variance weighted (IVW) method, and a series of sensitivity analyses and multi-dimensionality analyses were conducted to detect possible violations of the MR assumptions. This study used the IVW method to analyze the causal relationship between 15 micronutrients and OA. The results showed that copper (P = 0.535), selenium (P = 0.463), folic acid (P = 0.664), carotene (P = 0.706), potassium (P = 0.839), vitamin D (P = 0.941), vitamin C (P = 0.928), vitamin B12 (P = 0.859), iron (P = 0.496), vitamin E (P = 0.678), magnesium (P = 0.934), vitamin B6 (P = 0.027), calcium (P = 0.743), and vitamin A (P = 0.368) had no significant causal relationship with OA. Among them, vitamin B6 showed P < 0.05 in the pleiotropy test, indicating the presence of pleiotropy. In contrast, zinc exhibited a significant causal relationship with OA (P < 0.001, OR 95% CI = 1.044 [1.021–1.067]), with sensitivity analyses further validating the robustness and reliability of this finding. This study reveals a causal relationship between zinc and OA, identifying zinc as a risk factor for OA. It provides evidence of causality between zinc and OA, offering novel insights for clinical research, diagnosis, and treatment of OA.

24 September 2026 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
BZBaihe Zhang
Baihe Zhang
XYXinyue Yu
Xinyue Yu
ZZZipei Zhang
Zipei Zhang
XZXiaoling Zhou
Xiaoling Zhou
WZWenhai Zhao
Wenhai Zhao
CZChangwei Zhao
Changwei Zhao
Structural degeneration, pain and functional limitation in knee osteoarthritis (KOA) often diverge, which suggests that radiographic grading alone cannot explain the heterogeneous clinical course of the disease. Lower-limb alignment, gait strategy, muscle function, joint contact forces and real-world activity exposure jointly shape KOA onset, progression and treatment response. Artificial intelligence (AI) methods provide tools for integrating multimodal imaging, gait, wearable-sensor and clinical data, and can be combined with finite element analysis (FEA) and other computational biomechanical models. Conceptually, we propose an evidence-to-action framework that distinguishes AI-supported measurement, longitudinal prediction and intervention or decision utility, while separating AI-native methods from non-AI digital and computational biomechanical technologies. This structured narrative review synthesizes and critically interprets evidence on artificial intelligence in knee osteoarthritis from a biomechanical perspective, with an emphasis on biomechanical phenotyping across imaging, gait, wearable-sensor and clinical data, together with longitudinal risk stratification, diagnosis, progression prediction, rehabilitation feedback, perioperative management and clinical translation. Available studies indicate that artificial intelligence can support cartilage and meniscus segmentation, imaging-based grading, biomechanical load estimation, preoperative planning, and rehabilitation monitoring, although the strength and clinical maturity of the evidence vary substantially across these applications. Multimodal AI models have identified imaging, biomechanical, sensor-derived, and clinical features associated with structural progression, pain, and functional outcomes, but these associations should not be interpreted as causal or clinically actionable without longitudinal, external, and prospective validation. However, limited external validation, heterogeneous data acquisition, label bias, limited causal interpretability, limited use of patient-centered outcomes and poor workflow integration continue to constrain clinical use. Future AI-enabled KOA assessment should be grounded in biomechanical mechanisms and oriented toward patient outcomes and actionable clinical decisions. Translation will require standardized multimodal data, prospective validation and real-world utility evaluation.